HERVolution Therapeutics, a Copenhagen, Denmark-based darkish genome-focused biotechnology firm, raised $11.7M in Sequence A funding.
The spherical was led by Serum Institute of India (SII) with participation from the European Innovation Council (EIC) Fund and different buyers.
The corporate intends to make use of the funds to assist key actions, together with additional validating and demonstrating the worth of its human endogenous retroviruses (HERV)-targeting strategy, cGMP manufacturing in collaboration with SII, initiating Part 1 research of its lead asset, investigating indication growth alternatives, and increasing firm infrastructure to assist scientific trials.
Led by J. Robert Coleman, PhD, MBA, Chief Govt Officer, HERVolution Therapeutics (previously InProTher Aps) is a darkish genome-focused biotechnology firm offering new human endogenous retrovirus (HERV)-targeted immunotherapies to deal with ailments of ageing. With its proprietary engineering approaches, it has rationally redesigned HERV-antigens to yield a brand new class of extremely immunogenic antigens to deal with most cancers, metabolic, and different aging-related ailments. Its staff has superior a powerful product growth pipeline, with lead program, IPT-001, anticipated to enter the clinic in 2025.
FinSMEs
19/12/2024
